Skip to content

Advertisement

Clinical/Translational Cancer Immunotherapy

Section edited by Dr. James L. Gulley

First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, combination therapies, and cell therapies.

Page 2 of 5
  1. Content type: Research article

    Durable remissions are observed in a fraction of metastatic melanoma patients treated with high-dose interleukin-2 (HD IL-2). Early studies reported overall (OR) and complete response (CR) rates of 16% and 8% ...

    Authors: Diwakar Davar, Fei Ding, Melissa Saul, Cindy Sander, Ahmad A. Tarhini, John M. Kirkwood and Hussein A. Tawbi

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:74

    Published on:

  2. Content type: Research article

    Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [comple...

    Authors: Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov and Merrick Ross

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:72

    Published on:

  3. Content type: Research article

    Accumulating pre-clinical data indicate that the efficient induction of antigen-specific cytotoxic CD8+ T cells characterizing viral infections is caused by cross-priming where initially infected DCs produce a...

    Authors: Anna Laurell, Maria Lönnemark, Einar Brekkan, Anders Magnusson, Anna Tolf, Anna Carin Wallgren, Bengt Andersson, Lars Adamson, Rolf Kiessling and Alex Karlsson-Parra

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:52

    Published on:

  4. Content type: Research article

    Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pe...

    Authors: Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis and Julie A. Stone

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:43

    Published on:

  5. Content type: Research article

    Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor ...

    Authors: Matthew J. Reilley, Ann Bailey, Vivek Subbiah, Filip Janku, Aung Naing, Gerald Falchook, Daniel Karp, Sarina Piha-Paul, Apostolia Tsimberidou, Siqing Fu, JoAnn Lim, Stacie Bean, Allison Bass, Sandra Montez, Luis Vence, Padmanee Sharma…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:35

    Published on:

  6. Content type: Research article

    Testicular cancer is the most common male neoplasm occurring in men between the ages of 20 and 34. Although germ-line testicular tumors respond favorably to current standard of care, testicular stromal cell (T...

    Authors: Robert Aguilar, Justin M. Johnson, Patrick Barrett and Vincent K. Tuohy

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:37

    Published on:

  7. Content type: Meeting report

    As healthcare costs continue to rise, there has been great interest in understanding and defining the value of current therapeutic strategies for the treatment of cancer. Cancer immunotherapy has emerged as a ...

    Authors: Howard L. Kaufman, Michael B. Atkins, Adam P. Dicker, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, William T. McGivney, Steven Silverstein, Jon M. Wigginton and Peter P. Yu

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:38

    Published on:

  8. Content type: Research article

    We have been developing a non-thermal, drug-free tumor therapy called Nano-Pulse Stimulation (NPS) that delivers ultrashort electric pulses to tumor cells which eliminates the tumor and inhibits secondary tumo...

    Authors: Richard Nuccitelli, Amanda McDaniel, Snjezana Anand, John Cha, Zachary Mallon, Jon Casey Berridge and Darrin Uecker

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:32

    Published on:

  9. Content type: Research article

    Exercise immunology has become a growing field in the past 20 years, with an emphasis on understanding how different forms of exercise affect immune function. Mechanistic studies are beginning to shed light on...

    Authors: Michael P. Gustafson, Ara Celi DiCostanzo, Courtney M. Wheatley, Chul-Ho Kim, Svetlana Bornschlegl, Dennis A. Gastineau, Bruce D. Johnson and Allan B. Dietz

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:30

    Published on:

  10. Content type: Research article

    Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogene...

    Authors: Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, Christoforos Haritos, Christoforos K. Vaxevanis, Eleftheria A. Anastasopoulou, Nicole Janssen, Niki Arnogiannaki, Alexandros Ardavanis, Graham Pawelec, Sonia A. Perez and Constantin N. Baxevanis

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:39

    Published on:

    The Erratum to this article has been published in Journal for ImmunoTherapy of Cancer 2017 5:48

  11. Content type: Research article

    T cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined. Here we report results ...

    Authors: Kristen M. Hege, Emily K. Bergsland, George A. Fisher, John J. Nemunaitis, Robert S. Warren, James G. McArthur, Andy A. Lin, Jeffrey Schlom, Carl H. June and Stephen A. Sherwin

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:22

    Published on:

  12. Content type: Research article

    Insufficient persistence and effector function of chimeric antigen receptor (CAR)-redirected T cells have been challenging issues for adoptive T cell therapy. Generating potent CAR T cells is of increasing imp...

    Authors: Ryan Urak, Miriam Walter, Laura Lim, ChingLam W. Wong, Lihua E. Budde, Sandra Thomas, Stephen J. Forman and Xiuli Wang

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:26

    Published on:

  13. Content type: Short report

    Monoclonal antibodies that block immune regulatory proteins such as programmed death-1 (PD-1) have demonstrated remarkable efficacy in controlling the growth of multiple tumor types. Unresectable or metastatic...

    Authors: Evan J. Lipson, Mohammed T. Lilo, Aleksandra Ogurtsova, Jessica Esandrio, Haiying Xu, Patricia Brothers, Megan Schollenberger, William H. Sharfman and Janis M. Taube

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:23

    Published on:

  14. Content type: Research article

    Adoptive T cell immunotherapy (ATCT) for cancer entails infusing patients with T cells that recognise and destroy tumour cells. Efficient engraftment of T cells and persistence in the circulation correlate wit...

    Authors: Gray Kueberuwa, Hannah Gornall, Erik Marcelo Alcantar-Orozco, Deborah Bouvier, Zainul Abedin Kapacee, Robert Edward Hawkins and David Edward Gilham

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:14

    Published on:

  15. Content type: Research article

    We previously demonstrated that tumor irradiation potentiates cancer vaccines using genetic modification of tumor cells in murine tumor models. To investigate whether tumor irradiation augments the immune resp...

    Authors: Gilda G. Hillman, Lyndsey A. Reich, Shoshana E. Rothstein, Lisa M. Abernathy, Matthew D. Fountain, Kali Hankerd, Christopher K. Yunker, Joseph T. Rakowski, Eric Quemeneur and Philippe Slos

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:4

    Published on:

  16. Content type: Case report

    Renal medullary carcinoma (RMC) is a rare kidney tumor that occurs in adolescent and young adults, typically in association with sickle cell trait. RMC exhibits rapid disease progression, frequent metastases a...

    Authors: Kathryn E. Beckermann, Pradeep C. Jolly, Ju Y. Kim, Jennifer Bordeaux, Igor Puzanov, W. Kimryn Rathmell and Douglas B. Johnson

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:1

    Published on:

  17. Content type: Research article

    Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been prev...

    Authors: Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers, Anika E. Adeni, Hiroto Hatabu, Pasi A. Jänne, F. Stephen Hodi and Mark M. Awad

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:84

    Published on:

  18. Content type: Research article

    Ipilimumab and peginterferon alfa-2b are established systemic treatment options for melanoma that have distinct mechanisms of action. Given the need for improved therapies for advanced melanoma, we conducted a...

    Authors: Andrew S. Brohl, Nikhil I. Khushalani, Zeynep Eroglu, Joseph Markowitz, Ram Thapa, Y. Ann Chen, Ragini Kudchadkar and Jeffrey S. Weber

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:85

    Published on:

  19. Content type: Research article

    Immuno-oncology (I-O) therapies target the host immune system, providing the potential to choose a uniform dose and schedule across tumor types. However, dose selection for I-O agents usually occurs early in c...

    Authors: Shruti Agrawal, Yan Feng, Amit Roy, Georgia Kollia and Brian Lestini

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:72

    Published on:

  20. Content type: Research article

    Resistance to chemotherapy is a major obstacle in the effective treatment of cancer patients. B7-homolog 1, also known as programmed death ligand-1 (PD-L1), is an immunoregulatory protein that is overexpressed...

    Authors: Lauren Van Der Kraak, Gaurav Goel, Krishnaveni Ramanan, Christof Kaltenmeier, Lin Zhang, Daniel P. Normolle, Gordon J. Freeman, Daolin Tang, Katie S. Nason, Jon M. Davison, James D. Luketich, Rajeev Dhupar and Michael T. Lotze

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:65

    Published on:

Page 2 of 5

2016 Journal Metrics

Advertisement